Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elraglusib and Losartan with FOLFIRINOX in Untreated Metastatic Pancreatic Adenocarcinoma
NCT05077800Phase 2Active, not recruiting
- Start
- Mar 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of elraglusib in pancreatic adenocarcinoma (PDAC). Started Mar 2022; status: active, not recruiting.
02
Drugs
elraglusib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05077800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05077800.